TytoCare Gains FDA Clearance for Its AI Lung Crackle Detection

TytoCare has received an additional FDA clearance for a new AI-powered diagnostic capability, Tyto Insights for Crackle Detection. This capability is built on TytoCare’s database of lung sound recordings and driven by an innovative, AI-based algorithm. 

 

The Tyto Insights joins TytoCare’s existing suite of diagnostic tools, including Tyto Insights for Wheeze Detection, which was cleared by the FDA in 2023.

 

“The integration of AI into our diagnostic tools significantly enhances clinician efficiency and speed to diagnosis,” said Dedi Gilad, CEO and Co-Founder of TytoCare. “With our new AI-powered crackle detection algorithm, which was trained using data validated by pulmonologists.”

 

Tyto Insights for Crackle Detection is designed to help clinicians detect lung crackles in adults and children over two years old who may need attention during a virtual clinic visit. By identifying lung crackles in a virtual visit, providers can direct patients to the most appropriate follow-up treatment to manage their health.

 

During a virtual visit, the TytoCare solution uses this AI algorithm to analyze lung acoustic signals and identify exams with potential abnormal sounds indicative of crackles. If crackles are detected, the exam content is flagged, and providers are alerted to the presence of these abnormal lung sounds.

 

Tyto Insights for Crackle Detection will be added to TytoCare’s Home Smart Clinic and Pro Smart Clinic solutions will be available in September. 

 

TytoCare’s Home and Pro Smart Clinic are the only solutions that can replicate the full experience of the clinic virtually, including allowing clinicians to listen to a patient’s lungs, on top of the devices’ existing capabilities to remotely perform exams of the ears, throat, heart, and skin.